Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial Article Swipe
Yoshikazu Inoue
,
Takafumi Suda
,
Hideya Kitamura
,
Masaki Okamoto
,
Arata Azuma
,
Naohiko Inase
,
Masataka Kuwana
,
Shigeki Makino
,
Yasuhiko Nishioka
,
Takashi Ogura
,
Ayako Takizawa
,
Hiroyuki Ugai
,
Susanne Stowasser
,
Rozsa Schlenker‐Herceg
,
Tsutomu Takeuchi
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1016/j.rmed.2021.106574
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1016/j.rmed.2021.106574
In Japanese patients, nintedanib slowed ILD progression, evidenced by a reduction in the annual rate of decline in FVC vs placebo. The efficacy and safety of nintedanib in Japanese patients were consistent with the overall INBUILD population. CLINICALTRIALS.GOV: NCT02999178 (21-Dec-2016).
Related Topics
Concepts
Nintedanib
Medicine
Placebo
Exacerbation
Internal medicine
Clinical endpoint
Idiopathic pulmonary fibrosis
Hazard ratio
Subgroup analysis
Vital capacity
Population
Interstitial lung disease
Gastroenterology
Surgery
Randomized controlled trial
Lung
Diffusing capacity
Pathology
Confidence interval
Lung function
Alternative medicine
Environmental health
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.rmed.2021.106574
- OA Status
- hybrid
- Cited By
- 13
- References
- 37
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3194524700
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3194524700Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.rmed.2021.106574Digital Object Identifier
- Title
-
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-08-12Full publication date if available
- Authors
-
Yoshikazu Inoue, Takafumi Suda, Hideya Kitamura, Masaki Okamoto, Arata Azuma, Naohiko Inase, Masataka Kuwana, Shigeki Makino, Yasuhiko Nishioka, Takashi Ogura, Ayako Takizawa, Hiroyuki Ugai, Susanne Stowasser, Rozsa Schlenker‐Herceg, Tsutomu TakeuchiList of authors in order
- Landing page
-
https://doi.org/10.1016/j.rmed.2021.106574Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.rmed.2021.106574Direct OA link when available
- Concepts
-
Nintedanib, Medicine, Placebo, Exacerbation, Internal medicine, Clinical endpoint, Idiopathic pulmonary fibrosis, Hazard ratio, Subgroup analysis, Vital capacity, Population, Interstitial lung disease, Gastroenterology, Surgery, Randomized controlled trial, Lung, Diffusing capacity, Pathology, Confidence interval, Lung function, Alternative medicine, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
13Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 7, 2023: 4, 2022: 2Per-year citation counts (last 5 years)
- References (count)
-
37Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3194524700 |
|---|---|
| doi | https://doi.org/10.1016/j.rmed.2021.106574 |
| ids.doi | https://doi.org/10.1016/j.rmed.2021.106574 |
| ids.mag | 3194524700 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/34564020 |
| ids.openalex | https://openalex.org/W3194524700 |
| fwci | 2.29935214 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D044466 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Asian People |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D018450 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Disease Progression |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D004311 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Double-Blind Method |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D006801 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Humans |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D054990 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[5].qualifier_ui | Q000401 |
| mesh[5].descriptor_ui | D054990 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | mortality |
| mesh[5].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[6].qualifier_ui | Q000503 |
| mesh[6].descriptor_ui | D054990 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | physiopathology |
| mesh[6].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[7].qualifier_ui | Q000008 |
| mesh[7].descriptor_ui | D007211 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | administration & dosage |
| mesh[7].descriptor_name | Indoles |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D007211 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Indoles |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D017563 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Lung Diseases, Interstitial |
| mesh[10].qualifier_ui | Q000401 |
| mesh[10].descriptor_ui | D017563 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | mortality |
| mesh[10].descriptor_name | Lung Diseases, Interstitial |
| mesh[11].qualifier_ui | Q000503 |
| mesh[11].descriptor_ui | D017563 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | physiopathology |
| mesh[11].descriptor_name | Lung Diseases, Interstitial |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D012449 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Safety |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D013997 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Time Factors |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D016896 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Treatment Outcome |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D014797 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Vital Capacity |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D044466 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Asian People |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D018450 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Disease Progression |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D004311 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Double-Blind Method |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | Q000188 |
| mesh[20].descriptor_ui | D054990 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | drug therapy |
| mesh[20].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[21].qualifier_ui | Q000401 |
| mesh[21].descriptor_ui | D054990 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | mortality |
| mesh[21].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[22].qualifier_ui | Q000503 |
| mesh[22].descriptor_ui | D054990 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | physiopathology |
| mesh[22].descriptor_name | Idiopathic Pulmonary Fibrosis |
| mesh[23].qualifier_ui | Q000008 |
| mesh[23].descriptor_ui | D007211 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | administration & dosage |
| mesh[23].descriptor_name | Indoles |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D007211 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Indoles |
| mesh[25].qualifier_ui | Q000188 |
| mesh[25].descriptor_ui | D017563 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | drug therapy |
| mesh[25].descriptor_name | Lung Diseases, Interstitial |
| mesh[26].qualifier_ui | Q000401 |
| mesh[26].descriptor_ui | D017563 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | mortality |
| mesh[26].descriptor_name | Lung Diseases, Interstitial |
| mesh[27].qualifier_ui | Q000503 |
| mesh[27].descriptor_ui | D017563 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | physiopathology |
| mesh[27].descriptor_name | Lung Diseases, Interstitial |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D012449 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Safety |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D013997 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Time Factors |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D016896 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Treatment Outcome |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D014797 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Vital Capacity |
| type | article |
| title | Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial |
| biblio.issue | |
| biblio.volume | 187 |
| biblio.last_page | 106574 |
| biblio.first_page | 106574 |
| grants[0].funder | https://openalex.org/F4320310441 |
| grants[0].award_id | |
| grants[0].funder_display_name | Boehringer Ingelheim |
| grants[1].funder | https://openalex.org/F4320317302 |
| grants[1].award_id | |
| grants[1].funder_display_name | Boehringer Ingelheim Japan |
| topics[0].id | https://openalex.org/T10870 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| topics[1].id | https://openalex.org/T11571 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9846000075340271 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2737 |
| topics[1].subfield.display_name | Physiology |
| topics[1].display_name | Sarcoidosis and Beryllium Toxicity Research |
| topics[2].id | https://openalex.org/T12600 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9771999716758728 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2745 |
| topics[2].subfield.display_name | Rheumatology |
| topics[2].display_name | Eosinophilic Disorders and Syndromes |
| funders[0].id | https://openalex.org/F4320310441 |
| funders[0].ror | https://ror.org/00q32j219 |
| funders[0].display_name | Boehringer Ingelheim |
| funders[1].id | https://openalex.org/F4320317302 |
| funders[1].ror | https://ror.org/02r1d7x68 |
| funders[1].display_name | Boehringer Ingelheim Japan |
| is_xpac | False |
| apc_list.value | 3420 |
| apc_list.currency | USD |
| apc_list.value_usd | 3420 |
| apc_paid.value | 3420 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3420 |
| concepts[0].id | https://openalex.org/C2780171596 |
| concepts[0].level | 4 |
| concepts[0].score | 0.977136492729187 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q15149723 |
| concepts[0].display_name | Nintedanib |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.9254304766654968 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C27081682 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7913966178894043 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[2].display_name | Placebo |
| concepts[3].id | https://openalex.org/C2777014857 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7475002408027649 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1383410 |
| concepts[3].display_name | Exacerbation |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6754364371299744 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C203092338 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6028667092323303 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[5].display_name | Clinical endpoint |
| concepts[6].id | https://openalex.org/C2778341716 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5714957118034363 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2290446 |
| concepts[6].display_name | Idiopathic pulmonary fibrosis |
| concepts[7].id | https://openalex.org/C207103383 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5650181770324707 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[7].display_name | Hazard ratio |
| concepts[8].id | https://openalex.org/C187960798 |
| concepts[8].level | 3 |
| concepts[8].score | 0.530456006526947 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7631152 |
| concepts[8].display_name | Subgroup analysis |
| concepts[9].id | https://openalex.org/C55520419 |
| concepts[9].level | 5 |
| concepts[9].score | 0.477582722902298 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q660995 |
| concepts[9].display_name | Vital capacity |
| concepts[10].id | https://openalex.org/C2908647359 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4596220552921295 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[10].display_name | Population |
| concepts[11].id | https://openalex.org/C2777543607 |
| concepts[11].level | 3 |
| concepts[11].score | 0.4529147148132324 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1153419 |
| concepts[11].display_name | Interstitial lung disease |
| concepts[12].id | https://openalex.org/C90924648 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3489839434623718 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[12].display_name | Gastroenterology |
| concepts[13].id | https://openalex.org/C141071460 |
| concepts[13].level | 1 |
| concepts[13].score | 0.32556769251823425 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[13].display_name | Surgery |
| concepts[14].id | https://openalex.org/C168563851 |
| concepts[14].level | 2 |
| concepts[14].score | 0.3151072859764099 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[14].display_name | Randomized controlled trial |
| concepts[15].id | https://openalex.org/C2777714996 |
| concepts[15].level | 2 |
| concepts[15].score | 0.27246105670928955 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[15].display_name | Lung |
| concepts[16].id | https://openalex.org/C165637977 |
| concepts[16].level | 4 |
| concepts[16].score | 0.1571514904499054 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11067835 |
| concepts[16].display_name | Diffusing capacity |
| concepts[17].id | https://openalex.org/C142724271 |
| concepts[17].level | 1 |
| concepts[17].score | 0.12565091252326965 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[17].display_name | Pathology |
| concepts[18].id | https://openalex.org/C44249647 |
| concepts[18].level | 2 |
| concepts[18].score | 0.12105286121368408 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[18].display_name | Confidence interval |
| concepts[19].id | https://openalex.org/C3018587741 |
| concepts[19].level | 3 |
| concepts[19].score | 0.07241091132164001 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[19].display_name | Lung function |
| concepts[20].id | https://openalex.org/C204787440 |
| concepts[20].level | 2 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[20].display_name | Alternative medicine |
| concepts[21].id | https://openalex.org/C99454951 |
| concepts[21].level | 1 |
| concepts[21].score | 0.0 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[21].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/nintedanib |
| keywords[0].score | 0.977136492729187 |
| keywords[0].display_name | Nintedanib |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.9254304766654968 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/placebo |
| keywords[2].score | 0.7913966178894043 |
| keywords[2].display_name | Placebo |
| keywords[3].id | https://openalex.org/keywords/exacerbation |
| keywords[3].score | 0.7475002408027649 |
| keywords[3].display_name | Exacerbation |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6754364371299744 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[5].score | 0.6028667092323303 |
| keywords[5].display_name | Clinical endpoint |
| keywords[6].id | https://openalex.org/keywords/idiopathic-pulmonary-fibrosis |
| keywords[6].score | 0.5714957118034363 |
| keywords[6].display_name | Idiopathic pulmonary fibrosis |
| keywords[7].id | https://openalex.org/keywords/hazard-ratio |
| keywords[7].score | 0.5650181770324707 |
| keywords[7].display_name | Hazard ratio |
| keywords[8].id | https://openalex.org/keywords/subgroup-analysis |
| keywords[8].score | 0.530456006526947 |
| keywords[8].display_name | Subgroup analysis |
| keywords[9].id | https://openalex.org/keywords/vital-capacity |
| keywords[9].score | 0.477582722902298 |
| keywords[9].display_name | Vital capacity |
| keywords[10].id | https://openalex.org/keywords/population |
| keywords[10].score | 0.4596220552921295 |
| keywords[10].display_name | Population |
| keywords[11].id | https://openalex.org/keywords/interstitial-lung-disease |
| keywords[11].score | 0.4529147148132324 |
| keywords[11].display_name | Interstitial lung disease |
| keywords[12].id | https://openalex.org/keywords/gastroenterology |
| keywords[12].score | 0.3489839434623718 |
| keywords[12].display_name | Gastroenterology |
| keywords[13].id | https://openalex.org/keywords/surgery |
| keywords[13].score | 0.32556769251823425 |
| keywords[13].display_name | Surgery |
| keywords[14].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[14].score | 0.3151072859764099 |
| keywords[14].display_name | Randomized controlled trial |
| keywords[15].id | https://openalex.org/keywords/lung |
| keywords[15].score | 0.27246105670928955 |
| keywords[15].display_name | Lung |
| keywords[16].id | https://openalex.org/keywords/diffusing-capacity |
| keywords[16].score | 0.1571514904499054 |
| keywords[16].display_name | Diffusing capacity |
| keywords[17].id | https://openalex.org/keywords/pathology |
| keywords[17].score | 0.12565091252326965 |
| keywords[17].display_name | Pathology |
| keywords[18].id | https://openalex.org/keywords/confidence-interval |
| keywords[18].score | 0.12105286121368408 |
| keywords[18].display_name | Confidence interval |
| keywords[19].id | https://openalex.org/keywords/lung-function |
| keywords[19].score | 0.07241091132164001 |
| keywords[19].display_name | Lung function |
| language | en |
| locations[0].id | doi:10.1016/j.rmed.2021.106574 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S71995303 |
| locations[0].source.issn | 0954-6111, 1532-3064 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0954-6111 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Respiratory Medicine |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Respiratory Medicine |
| locations[0].landing_page_url | https://doi.org/10.1016/j.rmed.2021.106574 |
| locations[1].id | pmid:34564020 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Respiratory medicine |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/34564020 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5002422862 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3994-874X |
| authorships[0].author.display_name | Yoshikazu Inoue |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210160708 |
| authorships[0].affiliations[0].raw_affiliation_string | National Hospital Organization Kinki-Chuo Chest Medical Center, Clinical Research Center, Osaka, Japan. Electronic address: [email protected]. |
| authorships[0].institutions[0].id | https://openalex.org/I4210160708 |
| authorships[0].institutions[0].ror | https://ror.org/05jp74k96 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210137409, https://openalex.org/I4210160708 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | NHO Kinki Chuo Chest Medical Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Yoshikazu Inoue |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | National Hospital Organization Kinki-Chuo Chest Medical Center, Clinical Research Center, Osaka, Japan. Electronic address: [email protected]. |
| authorships[1].author.id | https://openalex.org/A5106084426 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Takafumi Suda |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I3123035732 |
| authorships[1].affiliations[0].raw_affiliation_string | Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine, Shizuoka, Japan. Electronic address: [email protected]. |
| authorships[1].institutions[0].id | https://openalex.org/I3123035732 |
| authorships[1].institutions[0].ror | https://ror.org/00ndx3g44 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I3123035732 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Hamamatsu University School of Medicine |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Takafumi Suda |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Hamamatsu University School of Medicine, Second Division, Department of Internal Medicine, Shizuoka, Japan. Electronic address: [email protected]. |
| authorships[2].author.id | https://openalex.org/A5075378562 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-5800-1175 |
| authorships[2].author.display_name | Hideya Kitamura |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210145082 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[2].institutions[0].id | https://openalex.org/I4210145082 |
| authorships[2].institutions[0].ror | https://ror.org/04154pe94 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210145082 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Kanagawa Cardiovascular and Respiratory Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Hideya Kitamura |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[3].author.id | https://openalex.org/A5086830418 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-9298-3504 |
| authorships[3].author.display_name | Masaki Okamoto |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I105296287 |
| authorships[3].affiliations[0].raw_affiliation_string | Kurume University School of Medicine, Division of Respirology, Neurology, and Rheumatology, Fukuoka, Japan. Electronic address: [email protected]. |
| authorships[3].institutions[0].id | https://openalex.org/I105296287 |
| authorships[3].institutions[0].ror | https://ror.org/057xtrt18 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I105296287 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Kurume University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Masaki Okamoto |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Kurume University School of Medicine, Division of Respirology, Neurology, and Rheumatology, Fukuoka, Japan. Electronic address: [email protected]. |
| authorships[4].author.id | https://openalex.org/A5053644656 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-0506-9966 |
| authorships[4].author.display_name | Arata Azuma |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: [email protected]. |
| authorships[4].institutions[0].id | https://openalex.org/I80188885 |
| authorships[4].institutions[0].ror | https://ror.org/00krab219 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Nippon Medical School |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Arata Azuma |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: [email protected]. |
| authorships[5].author.id | https://openalex.org/A5031476943 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Naohiko Inase |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210105781 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[5].institutions[0].id | https://openalex.org/I4210105781 |
| authorships[5].institutions[0].ror | https://ror.org/01r0bpx56 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210105781 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Hiratsuka Kyosai Hospital |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Naohiko Inase |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[6].author.id | https://openalex.org/A5075788011 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8352-6136 |
| authorships[6].author.display_name | Masataka Kuwana |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: [email protected]. |
| authorships[6].institutions[0].id | https://openalex.org/I80188885 |
| authorships[6].institutions[0].ror | https://ror.org/00krab219 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Nippon Medical School |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Masataka Kuwana |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: [email protected]. |
| authorships[7].author.id | https://openalex.org/A5025171057 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-1413-2819 |
| authorships[7].author.display_name | Shigeki Makino |
| authorships[7].affiliations[0].raw_affiliation_string | Osaka Medical and Pharmaceutical University, Mishima-Minami Hospital, Osaka, Japan. Electronic address: [email protected]. |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Shigeki Makino |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Osaka Medical and Pharmaceutical University, Mishima-Minami Hospital, Osaka, Japan. Electronic address: [email protected]. |
| authorships[8].author.id | https://openalex.org/A5025137523 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6311-1654 |
| authorships[8].author.display_name | Yasuhiko Nishioka |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I922474255 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Electronic address: [email protected]. |
| authorships[8].institutions[0].id | https://openalex.org/I922474255 |
| authorships[8].institutions[0].ror | https://ror.org/044vy1d05 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I922474255 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Tokushima University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Yasuhiko Nishioka |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Electronic address: [email protected]. |
| authorships[9].author.id | https://openalex.org/A5101978544 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Takashi Ogura |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210145082 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[9].institutions[0].id | https://openalex.org/I4210145082 |
| authorships[9].institutions[0].ror | https://ror.org/04154pe94 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210145082 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Kanagawa Cardiovascular and Respiratory Center |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Takashi Ogura |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan. Electronic address: [email protected]. |
| authorships[10].author.id | https://openalex.org/A5078286163 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-2581-2040 |
| authorships[10].author.display_name | Ayako Takizawa |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210122708 |
| authorships[10].affiliations[0].raw_affiliation_string | Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. Electronic address: [email protected]. |
| authorships[10].institutions[0].id | https://openalex.org/I4210122708 |
| authorships[10].institutions[0].ror | https://ror.org/02r1d7x68 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I1330995197, https://openalex.org/I4210122708 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Boehringer Ingelheim (Japan) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Ayako Takizawa |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. Electronic address: [email protected]. |
| authorships[11].author.id | https://openalex.org/A5079136395 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Hiroyuki Ugai |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210122708 |
| authorships[11].affiliations[0].raw_affiliation_string | Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. Electronic address: [email protected]. |
| authorships[11].institutions[0].id | https://openalex.org/I4210122708 |
| authorships[11].institutions[0].ror | https://ror.org/02r1d7x68 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I1330995197, https://openalex.org/I4210122708 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Boehringer Ingelheim (Japan) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Hiroyuki Ugai |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. Electronic address: [email protected]. |
| authorships[12].author.id | https://openalex.org/A5091576695 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Susanne Stowasser |
| authorships[12].countries | DE |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I1330995197 |
| authorships[12].affiliations[0].raw_affiliation_string | Boehringer Ingelheim International GmbH, Ingelheim, Germany. Electronic address: [email protected]. |
| authorships[12].institutions[0].id | https://openalex.org/I1330995197 |
| authorships[12].institutions[0].ror | https://ror.org/00q32j219 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I1330995197 |
| authorships[12].institutions[0].country_code | DE |
| authorships[12].institutions[0].display_name | Boehringer Ingelheim (Germany) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Susanne Stowasser |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Boehringer Ingelheim International GmbH, Ingelheim, Germany. Electronic address: [email protected]. |
| authorships[13].author.id | https://openalex.org/A5078029953 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Rozsa Schlenker‐Herceg |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210160255 |
| authorships[13].affiliations[0].raw_affiliation_string | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Electronic address: [email protected]. |
| authorships[13].institutions[0].id | https://openalex.org/I4210160255 |
| authorships[13].institutions[0].ror | https://ror.org/05kffp613 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I1330995197, https://openalex.org/I4210160255 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Boehringer Ingelheim (United States) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Rozsa Schlenker-Herceg |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Electronic address: [email protected]. |
| authorships[14].author.id | https://openalex.org/A5083314956 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-1111-8218 |
| authorships[14].author.display_name | Tsutomu Takeuchi |
| authorships[14].countries | JP |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[14].affiliations[0].raw_affiliation_string | Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: [email protected]. |
| authorships[14].institutions[0].id | https://openalex.org/I203951103 |
| authorships[14].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[14].institutions[0].country_code | JP |
| authorships[14].institutions[0].display_name | Keio University |
| authorships[14].author_position | last |
| authorships[14].raw_author_name | Tsutomu Takeuchi |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: [email protected]. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.rmed.2021.106574 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10870 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| related_works | https://openalex.org/W2783040524, https://openalex.org/W3082109398, https://openalex.org/W4367052859, https://openalex.org/W2505469254, https://openalex.org/W2979280297, https://openalex.org/W2984350958, https://openalex.org/W2962174921, https://openalex.org/W2119639538, https://openalex.org/W4327934586, https://openalex.org/W2315538569 |
| cited_by_count | 13 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 7 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 4 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 2 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.rmed.2021.106574 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S71995303 |
| best_oa_location.source.issn | 0954-6111, 1532-3064 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0954-6111 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Respiratory Medicine |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Respiratory Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.rmed.2021.106574 |
| primary_location.id | doi:10.1016/j.rmed.2021.106574 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S71995303 |
| primary_location.source.issn | 0954-6111, 1532-3064 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0954-6111 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Respiratory Medicine |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Respiratory Medicine |
| primary_location.landing_page_url | https://doi.org/10.1016/j.rmed.2021.106574 |
| publication_date | 2021-08-12 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2906077632, https://openalex.org/W2922513760, https://openalex.org/W2964216559, https://openalex.org/W2945521814, https://openalex.org/W2969734772, https://openalex.org/W2905745396, https://openalex.org/W2906678261, https://openalex.org/W2804065941, https://openalex.org/W3014590252, https://openalex.org/W2777674964, https://openalex.org/W2089756110, https://openalex.org/W2152974152, https://openalex.org/W2138871107, https://openalex.org/W2990986381, https://openalex.org/W2755069867, https://openalex.org/W2974960379, https://openalex.org/W3010166382, https://openalex.org/W2147322791, https://openalex.org/W2755105312, https://openalex.org/W2956457443, https://openalex.org/W2159148154, https://openalex.org/W6769153819, https://openalex.org/W2989387846, https://openalex.org/W2167383172, https://openalex.org/W2152628336, https://openalex.org/W2561968191, https://openalex.org/W2921133145, https://openalex.org/W2908889843, https://openalex.org/W6780076705, https://openalex.org/W2157714504, https://openalex.org/W2095657111, https://openalex.org/W2896189647, https://openalex.org/W2096455579, https://openalex.org/W2923176155, https://openalex.org/W3015103137, https://openalex.org/W2981181379, https://openalex.org/W3041475774 |
| referenced_works_count | 37 |
| abstract_inverted_index.a | 9 |
| abstract_inverted_index.In | 0 |
| abstract_inverted_index.by | 8 |
| abstract_inverted_index.in | 11, 17, 27 |
| abstract_inverted_index.of | 15, 25 |
| abstract_inverted_index.vs | 19 |
| abstract_inverted_index.FVC | 18 |
| abstract_inverted_index.ILD | 5 |
| abstract_inverted_index.The | 21 |
| abstract_inverted_index.and | 23 |
| abstract_inverted_index.the | 12, 33 |
| abstract_inverted_index.rate | 14 |
| abstract_inverted_index.were | 30 |
| abstract_inverted_index.with | 32 |
| abstract_inverted_index.annual | 13 |
| abstract_inverted_index.safety | 24 |
| abstract_inverted_index.slowed | 4 |
| abstract_inverted_index.INBUILD | 35 |
| abstract_inverted_index.decline | 16 |
| abstract_inverted_index.overall | 34 |
| abstract_inverted_index.Japanese | 1, 28 |
| abstract_inverted_index.efficacy | 22 |
| abstract_inverted_index.patients | 29 |
| abstract_inverted_index.placebo. | 20 |
| abstract_inverted_index.evidenced | 7 |
| abstract_inverted_index.patients, | 2 |
| abstract_inverted_index.reduction | 10 |
| abstract_inverted_index.consistent | 31 |
| abstract_inverted_index.nintedanib | 3, 26 |
| abstract_inverted_index.NCT02999178 | 38 |
| abstract_inverted_index.population. | 36 |
| abstract_inverted_index.progression, | 6 |
| abstract_inverted_index.(21-Dec-2016). | 39 |
| abstract_inverted_index.CLINICALTRIALS.GOV: | 37 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 15 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.87097971 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |